SynthesisPsychopharmacology2023
A systematic review of the role of clozapine for severe borderline personality disorder.
Synthesis in Psychopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- A critical review of the early clozapine trials published in German and a discussion of the many unresolved issues left by these trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The prevalence of antipsychotic polypharmacy and its associations with violent behaviors among forensic psychiatry patients.BMC psychiatry · 2026Article
- Clozapine as an Off-Label Treatment for Severe and Treatment-Resistant (Auto-)Aggressive Behavior in a 40-Year-Old Patient With Mild Intellecutal Disability and Borderline Personality Disorder.Case reports in psychiatry · 2026Article
- Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data.European child & adolescent psychiatry · 2025Article
- Borderline Personality Disorder and Self-Injurious Behaviours-Psychopharmacology bulletin · 2025Review
- Off-label Prescribing of Clozapine and Safety.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2025Review
- Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety.Patient preference and adherence · 2024Review
- Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes.Journal of clinical psychopharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleClozapine is a unique medication with a potential role in the treatment of severe borderline personality disorder (BPD).
objectivesThe review examines the effectiveness of clozapine as a medication for management for severe BPD with high risk of suicide, violence or imprisonment, and aims to help guide clinical practice in managing severe BPD.
methodsA database search of the terms "Clozapine" AND "BPD"; "Antipsychotics" AND "BPD"; "Clozapine" AND "Borderline Personality Disorder"; and "Antipsychotics" AND "Borderline Personality Disorder" were performed in CINAHL, Cochrane Library, Embase, Medline, PsychINFO, PubMed, and Web of Science. Full-text articles of clinical clozapine use for BPD were included for review.
resultsA total of 24 articles consisting of 1 randomised control trial, 10 non-controlled trials, and 13 case reports were identified. Most of the studies reported benefits from clozapine when used for severe BPD. Many of the studies focused on clozapine use in BPD patients at high risk of suicide. Results from these non-controlled and case reports support the use of clozapine in patients with severe BPD at high risk of suicide.
conclusionThere may be a role for clozapine in treating severe treatment refractory BPD, especially for those patients at high risk of suicide and frequent hospitalisations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.